The Oncology Institute, Inc. (TOI) reported a total revenue of $502.7 million for the fiscal year ending December 31, 2025, marking a 27.8% increase from $393.4 million in 2024. The growth was primarily driven by a significant rise in specialty pharmacy revenue, which surged by 49.6% to $269.2 million, alongside an 11.8% increase in patient services revenue, which reached $229 million. However, clinical trials and other revenue saw a decline of 47% to $4.6 million, attributed to a profit-sharing agreement with Helios Clinical Research that altered the revenue structure of that segment.
Despite the increase in revenue, TOI reported a net loss of $60.6 million for 2025, a slight improvement from the $64.7 million loss in the previous year. The loss from operations was $36.1 million, down from $60.1 million in 2024. The company attributed the reduced operating loss to a decrease in selling, general, and administrative expenses, which fell to 21% of total revenue from 27.4% in the prior year. This reduction was largely due to a significant decrease in share-based compensation expenses.
Operationally, TOI expanded its footprint, managing a population of approximately 2 million patients under value-based agreements across 17 markets in five states. The company operates 65 clinics and has a network of 207 providers in Florida. As of December 31, 2025, TOI employed 641 individuals, including 116 oncologists and advanced practice providers. The company continues to focus on enhancing its value-based care model, which accounted for over 46% of its revenue in 2025, and aims to further grow its market share through strategic partnerships and acquisitions.
Looking ahead, TOI expressed optimism about its growth trajectory, emphasizing its commitment to reducing the cost of oncology care while improving patient outcomes. The company plans to continue investing in its operational infrastructure and expanding its clinic network, although it acknowledges the challenges posed by rising healthcare costs and regulatory changes. The management remains focused on achieving profitability in the long term, despite the anticipated increase in operational expenses associated with its growth strategy.
About Oncology Institute, Inc.
The Oncology Institute, Inc. specializes in outpatient oncology care, offering fee-for-service and value-based contracts across multiple states. It operates clinics providing medical oncology, radiation therapy, pharmacy services, and clinical trials, primarily serving adult and senior populations. The company emphasizes evidence-based, cost-efficient care aligned with clinical guidelines, partnering with payors to manage oncology populations and improve outcomes while reducing costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.